Accretion Pharmaceuticals Limited H1 FY27 EBITDA Margin Up 606 bps

Accretion Pharmaceuticals Limited expanded its EBITDA margin by 606 basis points to 22.48% in the first half (H1) of financial year 2026-27 (FY27), as EBITDA, including other income, rose 72.28% to Rs 12.37 crore against 25.83% growth in income from operations to Rs 55.04 crore.

How did Accretion expand its EBITDA margin in H1 FY27?

Accretion expanded its EBITDA margin to 22.48% in H1 FY27 from 16.42% in H1 FY26, an increase of 606 basis points. EBITDA, or earnings before interest, tax, depreciation and amortisation, including other income, increased by Rs 5.19 crore to Rs 12.37 crore, while income from operations increased by Rs 11.30 crore to Rs 55.04 crore.

The reported margin change coincided with total expenditure rising 16.74% to Rs 42.81 crore, slower than the 25.83% increase in income from operations. Accretion attributed its sales growth to business expansion, volume growth, an improved product mix and customer additions, although the presentation does not quantify the contribution from any one driver.

Accretion reported other income of Rs 0.15 crore in H1 FY27, compared with Rs 0.11 crore a year earlier. Its profit-and-loss statement put total income at Rs 55.18 crore for H1 FY27, versus Rs 43.85 crore in H1 FY26, and specifies that the EBITDA measure includes other income.

Which costs rose more slowly than Accretion’s sales?

Accretion’s raw-material expense increased to Rs 37.51 crore in H1 FY27 from Rs 32.16 crore in H1 FY26, while employee cost rose to Rs 2.26 crore from Rs 2.06 crore. Other expenses increased to Rs 3.04 crore from Rs 2.45 crore, and these three categories made up the Rs 42.81 crore total expenditure for the period.

The Rs 6.14 crore increase in total expenditure was lower than the Rs 11.30 crore increase in income from operations. This reported gap between sales and cost growth accompanied the Rs 5.19 crore rise in EBITDA, but the presentation does not provide unit costs, product-level realisations or pricing data that would isolate individual cost or mix effects.

Accretion’s H1 FY27 EBITDA was also above the Rs 7.96 crore reported in H2 FY26, the second half of FY26. The EBITDA margin increased from 17.35% in H2 FY26 to 22.48% in H1 FY27, while income from operations rose from Rs 45.89 crore to Rs 55.04 crore across those reported half-year periods.

Depreciation rose to Rs 0.87 crore in H1 FY27 from Rs 0.40 crore in H1 FY26, and interest increased to Rs 0.65 crore from Rs 0.37 crore. Despite those higher charges, profit before tax increased 69.27% to Rs 10.85 crore from Rs 6.41 crore; no exceptional gain or loss was reported for either half year.

Did Accretion’s net profit margin also increase?

Accretion’s profit after tax, or PAT, margin rose 403 basis points to 14.90% in H1 FY27 from 10.87% in H1 FY26. PAT increased 72.63% to Rs 8.20 crore from Rs 4.75 crore, broadly matching the 72.28% increase in EBITDA and exceeding the 25.83% rise in income from operations.

Tax expense rose to Rs 2.65 crore from Rs 1.66 crore over the same comparison. Earnings per share, or EPS, increased 60.09% to Rs 7.38 from Rs 4.61, while net worth was reported at Rs 62.90 crore in H1 FY27 compared with Rs 46.60 crore in H1 FY26.

The H1 FY27 PAT margin was above both the 10.72% reported in H2 FY26 and the 10.79% recorded for FY26. The presentation provides no full-year FY27 profit forecast, so the half-year margin does not establish the outcome for the full financial year.

For annual context, Accretion reported an EBITDA margin of 16.89% in FY26, compared with 20.9% in FY25 and 23.1% in FY24. The H1 FY27 margin of 22.48% was 559 basis points above the FY26 full-year figure, while FY26 revenue increased to Rs 89.60 crore from Rs 57.40 crore in FY25.

How did Accretion’s domestic and export revenue mix change?

Accretion reported exports at 18.15% of H1 FY27 revenue, compared with 9.16% in H1 FY26. Domestic sales accounted for 81.85%, down from 90.84%, meaning the export share increased by 8.99 percentage points while domestic sales remained more than four-fifths of revenue.

The H1 FY27 export proportion was also above the annual export shares of 8.55% in FY26, 8.30% in FY25 and 7.28% in FY24. Accretion did not disclose export sales in rupees, destination markets, customer concentration or export profitability in the presentation.

The mix change occurred alongside a higher sales base, with income from operations of Rs 55.04 crore in H1 FY27 versus Rs 43.74 crore in H1 FY26. The presentation therefore supports a comparison of revenue shares, but not a calculation of domestic or export revenue amounts because it does not allocate the reported sales figure by segment in rupees.

H1 FY27 income from operations also exceeded H2 FY26 income from operations of Rs 45.89 crore by Rs 9.15 crore. These are consecutive half-year figures, whereas FY26 revenue of Rs 89.63 crore covers a full year and is not directly comparable with the H1 FY27 period.

What does Accretion plan to expand next?

Accretion’s proposed capital-expenditure plan involves leasing land adjacent to its existing facility and investing in machinery and equipment to expand production capacity. The presentation does not state the investment amount, funding source, commissioning schedule or targeted capacity addition for this proposal.

Accretion also plans product-portfolio diversification across formulations, dosage forms and therapeutic segments, alongside own-brand development through product development, promotion and wider market penetration. Management says a higher share of own-brand products is intended to support better long-term profit margins, but it does not disclose the current own-brand share or a quantitative margin target.

Global expansion is part of the roadmap through product registrations, regulatory approvals and strategic export partnerships. That plan follows the increase in exports to 18.15% of H1 FY27 revenue, but the presentation identifies no countries, registration milestones, approvals or partner agreements.

Accretion further plans to extend domestic and international distribution through channel partners, distributors and strategic business alliances. With domestic sales representing 81.85% of H1 FY27 revenue, the company has not provided a target number of new distributors, a market-share goal or a timeline for the distribution programme.

Conclusion

Accretion’s H1 FY27 result showed profitability rising faster than sales: income from operations grew 25.83% to Rs 55.04 crore while total expenditure increased 16.74% to Rs 42.81 crore. EBITDA increased 72.28% to Rs 12.37 crore, PAT rose 72.63% to Rs 8.20 crore, and the export share of revenue doubled year on year to 18.15%.

The next disclosed matters to watch are execution of the adjacent-land and machinery proposal, progress in own-brand development and product diversification, and international expansion through registrations and export partnerships. Accretion has outlined these initiatives but has not disclosed their spending, timing, capacity impact, own-brand target or country-specific milestones.